# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst David Nierengarten reiterates Nuvalent (NASDAQ:NUVL) with a Outperform and maintains $99 price target.
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for ...
JP Morgan analyst Anupam Rama maintains Nuvalent (NASDAQ:NUVL) with a Overweight and raises the price target from $90 to $100.
Barclays analyst Carter Gould initiates coverage on Nuvalent (NASDAQ:NUVL) with a Overweight rating and announces Price Targ...
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for ...